Biophytis Reports First-Half Financial Results and Updates on Business Activities

Paris (France) and Cambridge (Massachusetts, USA), September 30, 2024– Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on age-related diseases, published its financial results for the first half of 2024 and provided an update on key achievements.

Stanislas Veillet, CEO, highlighted significant strides made, including the launch of the OBA clinical program for obesity and an exclusive licensing agreement with Blanver for Latin America. These steps aim to advance their lead drug candidate, BIO101.

Financially, Biophytis reported a reduced net loss of €5.7 million for the first half of 2024, down from €7.8 million in 2023. The company also extended its bond financing line, securing funds for future growth.

Despite financial market challenges, Biophytis remains committed to progressing its clinical trials, particularly in obesity and Duchenne muscular dystrophy, while seeking additional partnerships for broader market reach.